People In Brief
This article was originally published in The Gray Sheet
Executive Summary
Edwards Lifesciences restructuring: Cardiovascular technology firm announces planned mid-year departures of corporate VPs Anita B. Bessler, Stuart L. Foster and Alex Martin, along with "strengthened alignment" into a business-unit organizational structure. Corporate VPs Donald E. Bobo, Paul C. Redmond, Carlyn D. Solomon and Larry L. Wood will take on additional U.S. sales, marketing and operational duties in their units, reporting to CEO Michael A. Mussallem. Bessler and Foster will continue in advisory roles with the company
You may also be interested in...
ev3, FoxHollow Merger Creates Peripheral Vascular Leviathan
Endovascular device makers ev3 and FoxHollow are combining their respective strong European and U.S. sales forces in a merger announced July 22
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.